Robert C. Reynolds;Ab;Cecil D. Kwong;Subramaniam Ananthan;Yuhua Huang;Vinay M. Girijavallabhan;Ashok Arasappan;Francisco Velazquez;F. George Njoroge;Frank Bennett;Joseph A. Maddry;Hollis S. Kezar, III
发明人:
Ashok Arasappan,F. George Njoroge,Cecil D. Kwong,Subramaniam Ananthan,Frank Bennett,Francisco Velazquez,Vinay M. Girijavallabhan,Yuhua Huang,Hollis S. Kezar, III,Joseph A. Maddry,Robert C. Reynolds,Ab
申请号：
US13579399
公开号：
US09433621B2
申请日:
2011.02.18
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.
